Frost & Sullivan recognizes BD with 2015 North American Frost & Sullivan Award for New Product Innovation

Based on its recent analysis of the intravenous drug delivery devices market, Frost & Sullivan recognizes BD (Becton, Dickinson and Company) with the 2015 North American Frost & Sullivan Award for New Product Innovation. The company's BD Intelliport™ System is the industry's first medication management system designed to overcome long-standing challenges associated with the administration of manual intravenous bolus injections. By offering enhanced automated documentation, dose measurement, drug identification, and real-time allergy alerts to the clinician, the BD Intelliport™ System is poised to address the most relevant challenges in the intravenous drug delivery market.

"More than 50 percent of the total medication errors in drug administration occur due to incorrect dose discharge, drug substitution and insertion errors; incorrect dose and substitution errors constituted almost 60 percent of these errors," said Frost & Sullivan Research Analyst Karan Verma. "The BD Intelliport™ System addresses this through fully automated drug identification and dose measurement, which may help manage the risks of syringe swap and incorrect dose measurement."

BD developed the BD Intelliport™ System in partnership with CRISI Medical Systems with an aim to facilitate safe and effective intravenous drug delivery. The BD Intelliport™ System automatically captures IV injectable drug name and concentration, and performs real-time, patient-specific allergy checking upon syringe connection; measures and displays the dose as it is delivered; records time of administration; and wirelessly sends necessary information directly to the patient's electronic medical record. BD acquired CRISI Medical Systems on March 2, 2015.

At the heart of this innovative new system is the BD Intelliport™ Injection Site, which has a unique barcode reading feature that automatically identifies the medication and concentration contained within a specially encoded syringe as a byproduct of existing clinical workflow. This feature eliminates the need for manual barcode scanning of syringes, enables audible confirmation that the correct drug is about to be given, and facilitates real-time drug allergy checks and alerts. Knowing the exact time each IV injection is given also allows the system to provide accurate and automated re-dosing reminders.

This new system enhances BD's already impressive and ever-expanding portfolio of end-to-end intravenous medication safety offerings.

"BD has witnessed rapid market adoption of its syringes and catheters because of their very high reliability and an ever-expanding consumer base," observed Verma. "It hopes for similar success with the BD Intelliport™ System."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

"BD has done a remarkably good job of understanding customer needs in the Intravenous Drug Delivery Devices market and developing an innovative new product to address those needs," said Frost & Sullivan Global President & Managing Partner Krishna Srinivasan. "It's BD Intelliport™ System is uniquely positioned for sustained success because it addresses the core issues that customers care about—patient safety, documentation accuracy and workflow efficiency."

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.